title: DBZ blocks LPS-induced monocyte activation and foam cell formation via inhibiting nuclear factor-ĸB.
abstract: OBJECTIVE
  It has been widely accepted that chronic inflammation plays important roles in the atherogenesis. Danshensu Bingpian Zhi (DBZ) is a novel synthetic compound derived from the traditional Chinese medicine (TCM) formula Fu Fang Dan Shen (FFDS), which is effective on atherosclerosis clinically. We hypothesized that DBZ possessed the anti-atherosclerosis potentials. Here, we examined the inhibitory effects of DBZ on LPS-induced monocyte activation and foam cell formation.
  
  
  METHODS
  The effects of DBZ were assessed on LPS-induced inflammatory factors expression in monocyte/macrophage. Activation of NF-κB and AP-1 was analyzed by luciferase reporter assay and signaling pathway of NF-κB was investigated to elucidate mechanisms underlying DBZ mediated anti-inflammatory activity. Effects of DBZ on macrophage lipid accumulation were evaluated in native LDL and LPS co-incubated macrophages.
  
  
  RESULTS
  DBZ inhibited LPS-induced inflammatory factors expression dose dependently in monocytes. DBZ inhibited NF-κB activation strongly and AP-1 slightly. DBZ suppressed the LPS-induced degradation of IκBα, thereby decreasing the translocation of p65 to nucleus. Furthermore, DBZ suppressed LPS-activated macrophages lipid accumulation, partly due to inhibiting the expression of LPS-induced aP2 and ADRP in macrophges.
  
  
  CONCLUSIONS
  These results demonstrate that DBZ has potentials on anti-atherosclerosis by suppressing monocyte activation and foam cell formation.
authors.affiliation: Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry and College of Life Sciences, Beijing Normal University, Beijing, P.R. China.
authors.forename: Xinni
authors.initials: X
authors.lastname: Xie
authors.forename: Shixiang
authors.initials: S
authors.lastname: Wang
authors.forename: Lei
authors.initials: L
authors.lastname: Xiao
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Jin
authors.initials: J
authors.lastname: Liu
authors.forename: Xuji
authors.initials: X
authors.lastname: Shen
authors.forename: Dacheng
authors.initials: D
authors.lastname: He
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Zheng
authors.forename: Yonggong
authors.initials: Y
authors.lastname: Zhai
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001892:Camphanes / Q000494:pharmacology*; D002478:Cells, Cultured; D005487:Foam Cells / Q000166:cytology / Q000187:drug effects; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008516:Medicine, Chinese Traditional; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D010666:Phenylpropionates / Q000494:pharmacology*; D018808:Transcription Factor AP-1 / Q000378:metabolism; D051996:Transcription Factor RelA / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D001892:Camphanes; D015850:Interleukin-6; D008070:Lipopolysaccharides; D016328:NF-kappa B; D010666:Phenylpropionates; D018808:Transcription Factor AP-1; D051996:Transcription Factor RelA; C571351:danshensu bingpian zhi; D009569:Nitric Oxide